X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs PFIZER - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS PFIZER NOVARTIS/
PFIZER
 
P/E (TTM) x 360.9 31.2 1,157.6% View Chart
P/BV x 17.8 5.0 358.5% View Chart
Dividend Yield % 1.6 0.7 248.5%  

Financials

 NOVARTIS   PFIZER
EQUITY SHARE DATA
    NOVARTIS
Mar-16
PFIZER
Mar-16
NOVARTIS/
PFIZER
5-Yr Chart
Click to enlarge
High Rs9822,724 36.0%   
Low Rs5561,611 34.5%   
Sales per share (Unadj.) Rs252.9440.9 57.4%  
Earnings per share (Unadj.) Rs62.148.7 127.6%  
Cash flow per share (Unadj.) Rs63.375.8 83.5%  
Dividends per share (Unadj.) Rs10.0015.00 66.7%  
Dividend yield (eoy) %1.30.7 187.9%  
Book value per share (Unadj.) Rs363.6462.9 78.5%  
Shares outstanding (eoy) m31.9645.75 69.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.04.9 61.9%   
Avg P/E ratio x12.444.5 27.8%  
P/CF ratio (eoy) x12.228.6 42.5%  
Price / Book Value ratio x2.14.7 45.2%  
Dividend payout %16.130.8 52.2%   
Avg Mkt Cap Rs m24,58099,163 24.8%   
No. of employees `0000.82.9 26.0%   
Total wages/salary Rs m1,8012,758 65.3%   
Avg. sales/employee Rs Th10,748.96,981.7 154.0%   
Avg. wages/employee Rs Th2,395.2954.5 250.9%   
Avg. net profit/employee Rs Th2,641.1771.1 342.5%   
INCOME DATA
Net Sales Rs m8,08320,170 40.1%  
Other income Rs m829857 96.7%   
Total revenues Rs m8,91321,028 42.4%   
Gross profit Rs m2344,310 5.4%  
Depreciation Rs m371,239 3.0%   
Interest Rs m25 34.6%   
Profit before tax Rs m1,0253,923 26.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m170-   
Extraordinary Inc (Exp) Rs m1,69699 1,715.7%   
Tax Rs m7521,794 41.9%   
Profit after tax Rs m1,9862,228 89.2%  
Gross profit margin %2.921.4 13.6%  
Effective tax rate %73.445.7 160.4%   
Net profit margin %24.611.0 222.5%  
BALANCE SHEET DATA
Current assets Rs m12,67816,299 77.8%   
Current liabilities Rs m2,4337,594 32.0%   
Net working cap to sales %126.743.2 293.7%  
Current ratio x5.22.1 242.8%  
Inventory Days Days3365 50.1%  
Debtors Days Days2226 87.3%  
Net fixed assets Rs m698,622 0.8%   
Share capital Rs m160458 34.9%   
"Free" reserves Rs m11,46020,722 55.3%   
Net worth Rs m11,62121,180 54.9%   
Long term debt Rs m025 0.0%   
Total assets Rs m14,40029,137 49.4%  
Interest coverage x570.5755.5 75.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.7 81.1%   
Return on assets %13.87.7 180.1%  
Return on equity %17.110.5 162.5%  
Return on capital %23.619.0 124.1%  
Exports to sales %0.70.1 1,251.8%   
Imports to sales %18.617.5 106.4%   
Exports (fob) Rs m6012 501.7%   
Imports (cif) Rs m1,5033,526 42.6%   
Fx inflow Rs m18652 360.7%   
Fx outflow Rs m1,821140 1,300.8%   
Net fx Rs m-1,635-88 1,850.4%   
CASH FLOW
From Operations Rs m2,5313,436 73.7%  
From Investments Rs m-8,270-6,991 118.3%  
From Financial Activity Rs m-386-619 62.3%  
Net Cashflow Rs m-6,125-4,174 146.7%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 63.9 117.4%  
Indian inst/Mut Fund % 2.0 7.5 26.7%  
FIIs % 1.6 4.9 32.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 23.7 90.7%  
Shareholders   41,647 85,207 48.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare NOVARTIS With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Feb 21, 2018 03:35 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS 8-QTR ANALYSIS

COMPARE NOVARTIS WITH

MARKET STATS